Philipp Höhn

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Waldemar H. Uhl · 9 shared papers, 2018–2024 · strength 1.38
   • Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
   • Paper Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associ… DOI 10.21037/acr-22-108↗
   • Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
2. Chris Braumann · 8 shared papers, 2018–2024 · strength 1.18
   • Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
   • Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
   • Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
3. Andreas Minh Luu · 5 shared papers, 2018–2021 · strength 0.63
   • Paper Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX. DOI 10.1159/000509231↗
   • Paper Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. DOI 10.21037/jgo-20-433↗
   • Paper Prognostic value and impact of cerebral metastases in pancreatic cancer. DOI 10.1080/00015458.2018.1549379↗
4. Marie Buchholz · 3 shared papers, 2023–2024 · strength 0.55
   • Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
   • Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
   • Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
5. Britta Majchrzak‐Stiller · 3 shared papers, 2023–2024 · strength 0.55
   • Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
   • Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
   • Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
6. Johanna B. Munding · 4 shared papers, 2018–2021 · strength 0.48
   • Paper Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX. DOI 10.1159/000509231↗
   • Paper Prognostic value and impact of cerebral metastases in pancreatic cancer. DOI 10.1080/00015458.2018.1549379↗
   • Paper Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pa… DOI 10.1159/000497827↗
7. Stephan A. Hahn · 2 shared papers, 2023–2024 · strength 0.38
   • Paper Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetio… DOI 10.3390/cancers16142612↗
   • Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
8. Athanasios Zamparas · 1 shared paper, 2023 · strength 0.20
   • Paper Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associ… DOI 10.21037/acr-22-108↗
9. Anke Reinacher‐Schick · 2 shared papers, 2018–2019 · strength 0.20
   • Paper Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pa… DOI 10.1159/000497827↗
   • Paper FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. DOI 10.21037/jgo.2018.01.07↗
10. Hanns Möhler · 1 shared paper, 2023 · strength 0.17
    • Paper GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway i… DOI 10.1111/jcmm.17825↗
11. Sven‐Thorsten Liffers · 1 shared paper, 2024 · strength 0.17
    • Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
12. Theodoros Kolokotronis · 1 shared paper, 2024 · strength 0.17
    • Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
13. Matthias Glanemann · 1 shared paper, 2024 · strength 0.17
    • Paper Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as… DOI 10.3390/cancers16152726↗
14. Orlin Belyaev · 1 shared paper, 2021 · strength 0.15
    • Paper Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. DOI 10.21037/jgo-20-433↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.